Kominsky Scott L, Argani Pedram, Korz Dorian, Evron Ella, Raman Venu, Garrett Elizabeth, Rein Alan, Sauter Guido, Kallioniemi Olli-P, Sukumar Saraswati
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Oncogene. 2003 Apr 3;22(13):2021-33. doi: 10.1038/sj.onc.1206199.
Claudins are transmembrane proteins that seal tight junctions, and are critical for maintaining cell-to-cell adhesion in epithelial cell sheets. However, their role in cancer progression remains largely unexplored. Here, we report that Claudin-7 (CLDN-7) expression is lower in invasive ductal carcinomas (IDC) of the breast than in normal breast epithelium, as determined by both RT-PCR (9/10) and Western analysis (6/8). Immunohistochemical (IHC) analysis of ductal carcinoma in situ (DCIS) and IDC showed that the loss of CLDN-7 expression correlated with histological grade in both DCIS (P<0.001, n=38) and IDC (P=0.014, n=31), occurring predominantly in high-grade (Nuclear and Elston grade 3) lesions. Tissue array analysis of 355 IDC cases further confirmed the inverse correlation between CLDN-7 expression and histological grade (P=0.03). This pattern of expression is consistent with the biological function of CLDN-7, as greater discohesion is typically observed in high-grade lesions. In line with this observation, by IHC analysis, CLDN-7 expression was lost in the vast majority (13/17) of cases of lobular carcinoma in situ, which is defined by cellular discohesion. In fact, inducing disassociation of MCF-7 and T47D cells in culture by treating with HGF/scatter factor resulted in a loss of CLDN-7 expression within 24 h. Silencing of CLDN-7 expression correlated with promoter hypermethylation as determined by methylation-specific PCR (MSP) and nucleotide sequencing in breast cancer cell lines (3/3), but not in IDCs (0/5). In summary, these studies provide insight into the potential role of CLDN-7 in the progression and ability of breast cancer cells to disseminate.
闭合蛋白是一类跨膜蛋白,可封闭紧密连接,对于维持上皮细胞层中细胞间的黏附至关重要。然而,它们在癌症进展中的作用在很大程度上仍未得到探索。在此,我们报告称,通过逆转录聚合酶链反应(RT-PCR,9/10)和蛋白质免疫印迹分析(Western分析,6/8)确定,乳腺浸润性导管癌(IDC)中闭合蛋白-7(CLDN-7)的表达低于正常乳腺上皮。对导管原位癌(DCIS)和IDC的免疫组织化学(IHC)分析表明,CLDN-7表达缺失与DCIS(P<0.001,n=38)和IDC(P=0.014,n=31)的组织学分级相关,主要发生在高级别(核分级和埃尔斯顿分级3级)病变中。对355例IDC病例的组织芯片分析进一步证实了CLDN-7表达与组织学分级之间呈负相关(P=0.03)。这种表达模式与CLDN-7的生物学功能一致,因为在高级别病变中通常观察到更大程度的细胞离散。与此观察结果一致,通过IHC分析,在绝大多数(13/17)小叶原位癌病例中CLDN-7表达缺失,小叶原位癌的定义是细胞离散。事实上,在培养中用肝细胞生长因子/分散因子处理诱导MCF-7和T47D细胞解离,导致24小时内CLDN-7表达缺失。通过甲基化特异性PCR(MSP)和核苷酸测序确定,在乳腺癌细胞系中(3/3),CLDN-7表达沉默与启动子高甲基化相关,但在IDC中则不然(0/5)。总之,这些研究深入了解了CLDN-7在乳腺癌进展和癌细胞扩散能力中的潜在作用。